Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy
(docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung
cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as
EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene
rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14
skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20
S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypotheses are that
sacituzumab tirumotecan is: (1) superior to chemotherapy with respect to progression-free
survival (PFS) per RECIST 1.1 as assessed by BICR in NSCLC with EGFR mutations; and (2)
superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR
mutations.

Treatment Sites in Georgia